You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

ZYRTEC HIVES RELIEF Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zyrtec Hives Relief patents expire, and what generic alternatives are available?

Zyrtec Hives Relief is a drug marketed by J And J Consumer Inc and is included in one NDA.

The generic ingredient in ZYRTEC HIVES RELIEF is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and fifty-six suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zyrtec Hives Relief

A generic version of ZYRTEC HIVES RELIEF was approved as cetirizine hydrochloride by PADAGIS US on June 17th, 2008.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ZYRTEC HIVES RELIEF?
  • What are the global sales for ZYRTEC HIVES RELIEF?
  • What is Average Wholesale Price for ZYRTEC HIVES RELIEF?
Drug patent expirations by year for ZYRTEC HIVES RELIEF
Recent Clinical Trials for ZYRTEC HIVES RELIEF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityPhase 4
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare DivisionPhase 1
Indiana UniversityPhase 4

See all ZYRTEC HIVES RELIEF clinical trials

US Patents and Regulatory Information for ZYRTEC HIVES RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc ZYRTEC HIVES RELIEF cetirizine hydrochloride TABLET;ORAL 019835-005 Nov 16, 2007 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
J And J Consumer Inc ZYRTEC HIVES RELIEF cetirizine hydrochloride TABLET;ORAL 019835-006 Nov 16, 2007 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ZYRTEC HIVES RELIEF

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0058146 2001C/045 Belgium ⤷  Subscribe PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
0663828 C300085 Netherlands ⤷  Subscribe PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146 SPC/GB01/052 United Kingdom ⤷  Subscribe SPC/GB01/052:, EXPIRES: 20070205
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

ZYRTEC HIVES RELIEF Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Cetirizine Hydrochloride (Zyrtec)

Introduction to Cetirizine Hydrochloride

Cetirizine hydrochloride, commonly known by the brand name Zyrtec, is an antihistamine drug that reduces the natural chemical histamine in the body, alleviating symptoms such as sneezing, watery eyes, and runny nose associated with allergies and hives[1].

Global Market Size and Growth

As of 2023, the global cetirizine hydrochloride market was valued at approximately USD 6.213 billion. This market is projected to grow at a Compounded Annual Growth Rate (CAGR) of 2.2% to reach USD 7.236 billion by 2030, and further to USD 8.0 billion by 2034, with a CAGR of 2.6% from 2024 to 2034[3].

Key Drivers of Market Growth

The growth of the cetirizine hydrochloride market is driven by several factors:

Increasing Incidence of Allergic Conditions

The high prevalence of allergic conditions such as allergic rhinitis, allergic conjunctivitis, and eczema is a significant driver. According to the American Academy of Allergy Asthma and Immunology, allergic rhinitis affects around 10% to 30% of the global population, with North America having the highest rate[1].

Advancements in Healthcare Infrastructure

Improvements in healthcare infrastructure, particularly in regions like North America, Europe, and the Asia Pacific, have increased access to antihistamine medications, contributing to market growth[3].

Availability of Generic Versions

The availability of generic versions of cetirizine hydrochloride has made the drug more accessible and affordable, further boosting market growth[3].

Regional Market Dynamics

North America

North America holds a dominant position in the global cetirizine hydrochloride market due to the high prevalence of hay fever and allergic conjunctivitis in the U.S. The region accounts for a significant share of the market, driven by the strong healthcare infrastructure and high incidence of allergic conditions[1][4].

Europe and Asia Pacific

Europe and the Asia Pacific are also key regions driving market growth. The Asia Pacific, in particular, presents significant opportunities due to increasing healthcare expenditure and growing awareness about allergy management[3].

Financial Trajectory and Budget Impact

Revenue and Growth Projections

The market is expected to grow from USD 6.213 billion in 2023 to USD 7.236 billion by 2030, with a CAGR of 2.2%. By 2034, the market is projected to reach USD 8.0 billion, growing at a CAGR of 2.6% from 2024 to 2034[3].

Budget Impact in Emergency Department Settings

The adoption of intravenous cetirizine hydrochloride in emergency department settings has shown a positive budget impact. For instance, in one scenario, the adoption of IV cetirizine resulted in a positive net budget impact of $27,876, primarily due to reduced operational costs and increased revenue from treating additional patients[2].

Challenges and Opportunities

Threat of New Medications

The development of new medications could potentially slow the growth rate of the cetirizine hydrochloride market. However, the established safety profile and effectiveness of cetirizine hydrochloride are likely to maintain its market position[3].

Regulatory Frameworks

Stringent regulatory standards, particularly in regions like Europe, can pose challenges for market growth. Compliance with these regulations ensures the quality and safety of the drug, maintaining consumer trust[3].

Emerging Markets

Regions like the Asia Pacific, Latin America, and the Middle East and Africa present significant opportunities for market expansion due to increasing healthcare expenditure and growing awareness about allergy management[3].

Key Players and Market Strategies

Major players operating in the global cetirizine hydrochloride market include Johnson and Johnson, Mylan, Inc., Nicox S.A., Strides Shasun, Apotex, Inc., Teva UK Limited, Aurobindo Pharma Limited, Jubilant Life Sciences, Tris Pharma, Inc., and Cipla Ltd. These companies are focused on new product launches and strategic partnerships to enhance their market share. For example, McNeil Consumer Healthcare—a Johnson and Johnson Company—launched a convenient oral, dissolvable tablet to the Zyrtec portfolio of allergy-relief products in 2014[1].

Illustrative Statistics and Quotes

  • "Allergies are the sixth leading cause of chronic illness in the U.S., with over 50 million people suffering from allergies annually, which account for an expenditure of US$ 18 billion," according to the American College of Allergy, Asthma and Immunology[1].
  • The prevalence of pollen allergy or hay fever in children between the ages of 12-14 was 22.1% worldwide, with the highest rate of 33.3% in North America[1].
"According to the American Academy of Allergy Asthma and Immunology, 2015, allergic rhinitis affects around 10% to 30 % of the population worldwide." - Coherent Market Insights Analysis (2018)[1]

Key Takeaways

  • The global cetirizine hydrochloride market is valued at USD 6.213 billion in 2023 and is expected to grow to USD 7.236 billion by 2030.
  • The market is driven by the increasing prevalence of allergic disorders, advancements in healthcare infrastructure, and the availability of generic versions.
  • North America, Europe, and the Asia Pacific are key regions driving market growth.
  • The market faces challenges from new medication developments and stringent regulatory frameworks but presents significant opportunities in emerging markets.
  • The adoption of cetirizine hydrochloride in emergency department settings has shown a positive budget impact.

FAQs

What is the current market size of cetirizine hydrochloride?

The global cetirizine hydrochloride market was valued at approximately USD 6.213 billion in 2023[3].

What is the projected growth rate of the cetirizine hydrochloride market?

The market is expected to grow at a CAGR of 2.2% from 2023 to 2030 and at a CAGR of 2.6% from 2024 to 2034[3].

Which regions are driving the growth of the cetirizine hydrochloride market?

North America, Europe, and the Asia Pacific are the key regions driving market growth due to their high incidence of allergic conditions and robust healthcare infrastructure[3].

What are the main drivers of the cetirizine hydrochloride market?

The main drivers include the increasing prevalence of allergic disorders, advancements in healthcare infrastructure, and the availability of generic versions of the drug[3].

How does the adoption of IV cetirizine hydrochloride impact the budget in emergency department settings?

The adoption of IV cetirizine hydrochloride has shown a positive budget impact, primarily due to reduced operational costs and increased revenue from treating additional patients[2].

Sources Cited

  1. Coherent Market Insights - Global Cetirizine Hydrochloride Market Size And Forecast To 2026
  2. AHDB Online - Budget Impact of Intravenous Cetirizine Hydrochloride for the Treatment of Acute Urticaria in the Emergency Department Setting
  3. DrugPatentWatch - Cetirizine hydrochloride - Generic Drug Details
  4. Mordor Intelligence - Antihistamine Market Size & Share Analysis - Growth Trends

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.